Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07735338

Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke

To assess the diagnostic accuracy of a smartphone application in predicting heart attack or stroke within 3-4 days in high-risk patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

40 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University

Stanford, California, 94305, United States

Location contact

Sandra Tsai, MD

CONTACT

[email protected]

650-498-9000

Sandra Tsai, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be able to provide electronic or written informed consent and be able to effectively communicate and understand the study procedures, risks, and required activities.
  • Age 40 to 79 years.
  • Be willing to wear a smartwatch continuously for 18 months and comfortable with using wearable devices or other technologies that monitor their data over time.
  • Established ASCVD or at an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as anyone of the following:

i) Evidence of atherosclerotic CAD on CT or invasive coronary angiogram defined as a coronary artery stenosis ≥ 20% but <50% in the left main coronary artery or a stenosis ≥ 20% but <70% in any other major coronary artery.

ii) Coronary artery calcium score ≥ 100 Agatston units.

iii) High estimated10-year ASCVD risk ≥ 20% by pooled cohort equation.

iv) Intermediate estimated 10-year ASCVD risk 7.5% to <20% by pooled cohort equation with at least 2 of the following risk-enhancing factors:

  • A first degree relative with history of premature ASCVD (males, age <55 years; females, age <65 years).
  • History of premature menopause before age 40.
  • History of maternal pregnancy complications (defined as a history of either preeclampsia, gestational hypertension, or gestational diabetes).
  • South Asian ancestry.
  • Chronic inflammatory disorders (defined as either rheumatoid arthritis, systemic lupus erythematosus, psoriasis covering ≥10% of body surface area, Crohn's disease, ulcerative colitis, or HIV/AIDS).
  • High-sensitivity C-reactive protein (hsCRP) ≥2 mg/L documented in the 12 months preceding the screening visit, and, in absence of any underlying acute or inflammatory conditions.
  • Lipoprotein (a) ≥50 mg/dL or ≥125 nmol/L at any time before the screening visit.
  • Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2.
  • Ankle branchial index (ABI) <0.9 with no symptoms of intermittent claudication.
  • Metabolic syndrome: increased waist circumference, elevated triglycerides, elevated blood pressure, elevated glucose, and low HDL-C are factors

i. Diabetes

Exclusion criteria

  • The 10-year ASCVD risk <7.5%.
  • Elevated troponin at baseline.
  • Cognitive impairment.
  • Neurological disorders that would impair their ability to provide informed consent or adhere to study protocols.
  • Metastatic cancer or active cancer undergoing chemotherapy.
  • Terminal illness.
  • Pregnant women or women of childbearing potential not using contraception.
  • Current or past major psychiatric disorders (e.g., schizophrenia, bipolar disorder, severe depression) that could affect physiological or biometric data.
  • Surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.
  • Unwillingness or inability to comply with study procedures, including adherence to study visits, fasting blood draws and compliance with study protocol.
  • Residing in an inpatient facility or bedbound

Treatment and study plan

Smartphone application Antshrike

Device

All participants will wear a smart watch that has an application Antshrike, which will collect demographic data, health history, lifestyle factors, and biobehavioral data for 18 months.

Primary outcomes

  1. Number of ASCVD events

    Time frame: Baseline through 18 months

    ASCVD events include myocardial infarction (MI), ischemic stroke/transient ischemic attack (TIA), CV death, or clinically driven arterial revascularization or hospitalization.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Collaborators

  • Before Health Intelligence Ltd
  • Samsung Electronics Co., Ltd

Registry information

Official study title

Prospective Study of the Diagnostic Accuracy of a Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke (PREDICT-HS)

Acronym: PREDICT-HS

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jul 30, 2026
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.